Sanofi's Dupixent wins U.S. approval for bigger use
05/20/2022 | 02:42pm EDT
May 20 (Reuters) - Sanofi on Friday won expanded
U.S. approval for its best-selling Dupixent injection to treat
an allergic inflammation of the esophagus, the U.S. Food and
Drug Administration said.
(Reporting by Ludwig Burger; Additional reporting by Eva
Mathews; Editing by Maju Samuel)